Summary: The Centers for Medicare & Medicaid Services modified its osteogenic stimulators coverage policy, effective May 15, 2026. Here's what billing teams need to do.
CMS osteogenic stimulator coverage policy has been updated under a modified determination effective May 15, 2026. This policy governs Medicare reimbursement for electrical and ultrasonic bone growth stimulators—durable medical equipment used to promote healing in nonunion fractures, spinal fusion, and related indications. The policy does not list specific CPT or HCPCS codes in the data available for this post. Review the full policy at the source before updating your charge capture.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Osteogenic Stimulators |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Orthopedic surgery, neurosurgery, physical medicine & rehabilitation, DME suppliers |
| Key Action | Review your documentation standards and prior authorization workflows against the updated CMS coverage policy before May 15, 2026 |
CMS Osteogenic Stimulators Coverage Criteria and Medical Necessity Requirements 2026
Osteogenic stimulators sit at the intersection of durable medical equipment billing and surgical aftercare—which means claim denials here tend to be expensive and hard to overturn. CMS has long tied reimbursement for bone growth stimulators to strict medical necessity criteria, and this 2026 modification signals another tightening of those standards.
CMS generally divides osteogenic stimulators into two categories: electrical bone growth stimulators and ultrasonic bone growth stimulators. Electrical devices include both invasive (surgically implanted) and non-invasive (external) variants. Ultrasonic devices are non-invasive and typically applied externally at the fracture site.
For a claim to clear medical necessity review, the documentation must show a confirmed diagnosis supporting the clinical indication—most commonly a nonunion fracture with a defined number of weeks elapsed since the original injury, or a spinal fusion procedure meeting specific criteria. Vague clinical notes saying the patient "failed to heal normally" will not hold up. Your physicians need to document the fracture date, the treatment timeline, and any prior conservative interventions before a stimulator was ordered.
Prior authorization is a real exposure point here. Medicare Administrative Contractor policies on prior authorization for DME vary by region, and some MACs have been tightening requirements for osteogenic stimulators specifically. Confirm your MAC's local coverage determination requirements alongside this CMS modification. A national coverage policy change does not override or replace LCD-level requirements—both apply.
This coverage policy change also carries implications for how you document the ordering physician's narrative. CMS has historically required a detailed written order and supporting clinical documentation from the treating physician. If your DME supplier relationships depend on physician referrals for stimulators, make sure those referring physicians know what documentation CMS now expects before they sign the order.
CMS Osteogenic Stimulators Exclusions and Non-Covered Indications
CMS has historically excluded osteogenic stimulators from coverage in several clinical scenarios. These exclusions are worth knowing before you bill, because they account for a significant share of claim denials in this category.
Fresh fractures—meaning fractures that have not yet had adequate time for natural healing—are not covered. CMS defines nonunion by the number of weeks elapsed since injury, and billing a stimulator before that threshold is met is a fast path to denial and potential overpayment liability.
Electrical stimulation for conditions outside orthopedic nonunion and spinal fusion—such as chronic wounds or peripheral nerve regeneration—falls outside the Medicare coverage policy for osteogenic stimulators. These may be addressed under separate policies, but they are not covered here.
Ultrasonic stimulators for fresh fractures, even when the fracture is complex, are generally excluded. The clinical rationale is that standard healing is expected in acute fractures and medical necessity for acceleration has not been established to CMS's standard.
Spinal fusion cases require careful review. Not every fusion is covered—CMS has specified criteria around the number of levels fused, the diagnosis driving the fusion, and the type of fusion procedure. If your neurosurgery or orthopedic surgery practice is ordering stimulators post-fusion, audit those cases against the updated criteria before May 15, 2026.
Coverage Indications at a Glance
The policy data provided for this post does not include a granular indication-by-indication breakdown with specific codes. The table below reflects CMS's historically established coverage framework for osteogenic stimulators, which this modification builds on. Confirm each row against the full policy text before billing.
| Indication | Status | Notes |
|---|---|---|
| Nonunion fracture (defined elapsed time since injury) | Covered | Medical necessity documentation required; specific week threshold must be met |
| Failed spinal fusion | Covered | Criteria apply to number of levels, diagnosis, and procedure type |
| Acute / fresh fracture | Not Covered | Natural healing expected; stimulator not medically necessary at this stage |
| Congenital pseudarthrosis | Covered (conditional) | Less common; confirm with your MAC's LCD |
| Wound healing / chronic wounds | Not Covered under this policy | Addressed under separate CMS policies |
| Post-operative spinal fusion (prophylactic use) | Not Covered | Stimulator must be ordered for failure to heal, not as a preventive measure |
| Stress fractures | Not Covered | Insufficient evidence base for Medicare coverage |
CMS Osteogenic Stimulators Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull your MAC's current LCD on osteogenic stimulators before May 15, 2026. The CMS modification at the national level is the ceiling, but your MAC's local coverage determination may be more restrictive. Billing without confirming LCD alignment is a denial waiting to happen. |
| 2 | Audit your documentation templates for physician orders. A valid osteogenic stimulator claim requires a detailed written order from the treating physician, supported by clinical notes that establish the diagnosis, fracture or fusion timeline, and prior treatment history. If your current templates don't capture all of that, update them now—not after the first denial. |
| 3 | Verify prior authorization requirements with your DME supplier and MAC. Prior authorization workflows for osteogenic stimulators can differ significantly by region. If you are a DME supplier billing these devices directly, contact your MAC to confirm whether prior auth is required under the updated coverage policy for your jurisdiction. |
| 4 | Flag spinal fusion cases for secondary review. Spinal fusion stimulator claims carry above-average scrutiny. Build a secondary review step into your charge capture workflow for any claim where the indication is post-fusion. Confirm the procedure type, number of levels, and diagnosis align with CMS criteria before submitting. |
| 5 | Review your nonunion fracture claim submissions for timing accuracy. The elapsed time since original fracture injury is a hard requirement. Make sure your billing team is pulling the original fracture date—not the surgery date or the referral date—and calculating elapsed weeks correctly before submitting. |
| 6 | Update your denial management protocol. If osteogenic stimulator claims start denying at a higher rate after May 15, 2026, your team needs a clear escalation path. Document the specific denial reason codes and route them to whoever owns payer policy appeals. Don't let these age past timely filing while you figure out the new criteria. |
If your practice spans multiple specialties or you have high volume in orthopedics or neurosurgery, loop in your compliance officer before the effective date. This is a high-reimbursement DME category with active audit exposure, and the modification adds complexity that warrants a formal internal review.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Osteogenic Stimulators Under This Policy
The policy data provided for this post does not list specific CPT, HCPCS, or ICD-10 codes. Do not rely on this post for code-level billing guidance without pulling the full policy from the CMS source.
That said, osteogenic stimulator billing typically involves HCPCS Level II codes for the device itself (billed by DME suppliers) and CPT codes for any surgical implantation of invasive stimulators. ICD-10-CM diagnosis codes documenting nonunion fractures, failed fusions, and congenital pseudarthrosis are central to establishing medical necessity on these claims.
Where to Get the Authoritative Code List
Review the full policy at: https://app.payerpolicy.org/p/cms/65-v2
Cross-reference against your MAC's LCD for the complete list of covered and non-covered codes in your jurisdiction. The LCD will include the specific HCPCS codes recognized for reimbursement and the ICD-10-CM codes required to support medical necessity. Billing a device code without a mapped, LCD-approved diagnosis code is one of the most common reasons these claims deny.
What This Modification Means for Your Revenue Cycle
The real issue here is not just the policy change itself—it's the compounding effect of CMS modification plus MAC LCD variability plus DME supplier coordination. Osteogenic stimulator billing is one of those categories where the paper trail has to be airtight before you submit.
DME suppliers billing these devices directly carry significant exposure if the ordering physician's documentation doesn't meet the updated standard. The physician may think the order is sufficient. The claim may process initially. The audit comes later. That's the pattern with high-cost DME under CMS—initial payment, retrospective review, recoupment demand.
The May 15, 2026 effective date gives you a narrow window. If you're billing osteogenic stimulators in orthopedic surgery, neurosurgery, or as a DME supplier, treat this as a required workflow review—not an optional one.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.